GAL and neoplasm: Since anti-Gal is present in all humans who are not severely immunocompromised, anti-Gal/α-gal epitope immune-complexes may be considered as a platform for a variety of future immunotherapies, collectively called “α-gal therapies,” which include the following: amplification of viral vaccine efficacy, in situ conversion of tumors into vaccines against autologous tumor-associated antigens, accelerated repair and prevention of scar formation in skin and in post-MI injury to the myocardium, and protection against pathogens presenting α-gal or α-gal–like epitopes.